Clinical trials: Leukemia, Lymphocytic, Acute, T-Cell

Chronic Myeloproliferative Disorders, Graft Versus Host Disease

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

• Completed
• Age: 18 years and older
• Phase 3
• Results posted

RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.

Conditions

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma

Trial name

NCT00755040

Testing

cyclosporine ophthalmic emulsion

Where

5 sites in United States

Volunteers

164 people

Sponsor

Vanderbilt-Ingram Cancer Center